Vivimed Labs Ltd Surges to Upper Circuit Amid Strong Buying Pressure

Strong Price Movement and Trading Activity

On 13 Feb 2026, Vivimed Labs Ltd’s equity shares in the EQ series closed at ₹7.36, up ₹0.23 or 3.23% from the previous close. The stock’s price band was set at 5%, and it reached a high of ₹7.48 during the session, triggering the upper circuit limit. The total traded volume stood at approximately 1.46 lakh shares, with a turnover of ₹0.11 crore, indicating moderate trading activity given the stock’s micro-cap status.

This price action represents a continuation of the stock’s recent positive momentum, having gained 7.21% over the last two trading days. Notably, Vivimed Labs outperformed its sector by 3.25% and the Sensex by a significant margin, as the benchmark index declined by 0.98% on the same day.

Technical Indicators and Moving Averages

From a technical standpoint, the stock’s last traded price (LTP) remains above its 5-day moving average, signalling short-term bullishness. However, it continues to trade below its 20-day, 50-day, 100-day, and 200-day moving averages, suggesting that medium- and long-term trends have yet to confirm a sustained uptrend. This divergence highlights a cautious optimism among traders, with the immediate buying pressure not yet supported by broader trend strength.

Investor Participation and Liquidity Constraints

Despite the price surge, investor participation appears to be waning. Delivery volume on 12 Feb 2026 was recorded at 3.39 lakh shares, marking a sharp decline of 42.71% compared to the five-day average delivery volume. This drop in delivery volume indicates reduced commitment from investors holding shares for the longer term, which could temper the sustainability of the rally.

Liquidity remains a concern for Vivimed Labs, with the stock’s traded value representing just 2% of its five-day average traded value. This level of liquidity supports trade sizes of approximately ₹0.01 crore, which may limit the ability of larger institutional investors to build significant positions without impacting the price.

Regulatory Freeze and Unfilled Demand

The upper circuit hit triggered an automatic regulatory freeze on trading in Vivimed Labs shares for the remainder of the day, preventing further price appreciation and locking in the maximum permissible gain of 5% for the session. This freeze is a mechanism designed to curb excessive volatility and protect investors from speculative excesses.

Market participants noted significant unfilled demand at the upper circuit price, with buy orders exceeding sell orders by a wide margin. This imbalance underscores strong bullish sentiment, although the inability to transact beyond the circuit limit may frustrate some buyers and lead to pent-up demand in subsequent sessions.

Fundamental and Market Context

Vivimed Labs operates within the Pharmaceuticals & Drugs industry, a sector that has experienced mixed performance amid evolving regulatory landscapes and competitive pressures. The company’s micro-cap status, with a market capitalisation of ₹59.00 crores, places it in a niche segment where liquidity and analyst coverage are limited.

MarketsMOJO currently assigns Vivimed Labs a Mojo Score of 24.0, categorising it with a Strong Sell grade as of 5 Feb 2026, an upgrade from the previous Sell rating. This rating reflects concerns over the company’s fundamentals and valuation metrics despite recent price gains. The Market Cap Grade is 4, indicating a relatively low market capitalisation compared to peers.

Investors should weigh the recent technical strength against the fundamental caution advised by the Mojo Grade, considering the stock’s volatility and liquidity constraints before making investment decisions.

Outlook and Investor Considerations

While the upper circuit hit and strong intraday gains highlight renewed interest in Vivimed Labs, investors should approach with caution. The stock’s recent outperformance contrasts with its longer-term technical indicators and fundamental ratings. The decline in delivery volumes suggests that the rally may be driven more by short-term speculative buying than sustained investor conviction.

Liquidity constraints and the micro-cap nature of the stock mean that price movements can be exaggerated by relatively small trades, increasing volatility risk. Additionally, the regulatory freeze mechanism limits intraday upside, potentially leading to volatile price action in subsequent sessions as pent-up demand is released.

For investors considering exposure, it is advisable to monitor trading volumes, delivery trends, and any updates to the company’s fundamental outlook. Diversification and risk management remain paramount given the stock’s profile.

Summary

Vivimed Labs Ltd’s upper circuit hit on 13 Feb 2026 reflects strong buying pressure and a maximum daily gain of 3.23%, outperforming its sector and the Sensex. However, subdued delivery volumes and liquidity constraints temper the outlook. The stock remains below key moving averages, and its Strong Sell Mojo Grade advises caution. Regulatory trading freezes capped intraday gains, leaving unfilled demand that may influence future sessions. Investors should balance technical momentum with fundamental risks when evaluating this micro-cap pharmaceutical stock.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →